EpiSign and Geneyx Announce Partnership to Integrate Genomic and Epigenomic Analysis for Rare Disease
Collaboration brings EpiSign’s comprehensive DNA methylation episignature analysis together with the Geneyx genomic and multi-omics analysis platform LONDON, ON and HERZLIYA, Israel, Oct. 5, 2026 /PRNewswire/ — EpiSignInc. and GeneyxGenomex Ltd. today
